We recently published a list of the 13 Most Undervalued Blue Chip Stocks To Buy According To Analysts. In this article, we ...

The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like ...

Keytruda shows promise as a first line option in cervical cancer cutting patients' mortality risk by a third in a Phase 3 ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $117.96 which represents a slight increase of $2.10 or 1.81% from the prior close of $115.86. The stock opened at $115.8 and touched a ...

Merck (MRK) and Daiichi Sankyo (DSNKY) announce early results from a Phase 2 trial of lung cancer drug I-DXd, an antibody ...

Jefferies analyst Akash Tewari maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Merck & Company (MRK – Research Report) today. The company’s ...

As of 20 September at 1:40 pm GMT-4. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

As of 19 September at 9:54 am GMT-4. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.